Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
6.49
-0.36 (-5.26%)
At close: May 9, 2025, 4:00 PM
7.00
+0.51 (7.86%)
After-hours: May 9, 2025, 7:38 PM EDT
Tempest Therapeutics Employees
Tempest Therapeutics had 24 employees as of December 31, 2024. The number of employees increased by 7 or 41.18% compared to the previous year.
Employees
24
Change (1Y)
7
Growth (1Y)
41.18%
Revenue / Employee
n/a
Profits / Employee
-$1,743,458
Market Cap
22.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24 | 7 | 41.18% |
| Dec 31, 2023 | 17 | -2 | -10.53% |
| Dec 31, 2022 | 19 | 2 | 11.76% |
| Dec 31, 2021 | 17 | 3 | 21.43% |
| Dec 31, 2020 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TPST News
- 13 days ago - Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - GlobeNewsWire
- 20 days ago - Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - GlobeNewsWire
- 4 weeks ago - Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value - GlobeNewsWire
- 6 weeks ago - Tempest Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 2 months ago - FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP) - GlobeNewsWire
- 3 months ago - Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma - GlobeNewsWire
- 3 months ago - Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire